US-based biopharmaceutical company, RAPT Therapeutics’ stock surged more than 63% during the pre-market trading session on the US stock market’s Nasdaq after GSK Plc announced its $2.2 billion equity value acquisition deal, according to the official filing.

RAPT stock today

RAPT Therapeutics’ stock jumped more than 63% to $57.45 during the premarket trading session on the US stock market on Tuesday after the acquisition update, compared to $35.10 at the previous market close, according to MarketWatch data on Tuesday.

After Monday’s trading session, RAPT stock closed 9.04% higher at $35.10, according to the market data.

Shares of RAPT Therapeutics have lost 79% in the last five years. However, the company’s stock has given US market investors more than 265% in the last one-year period.

The biopharma stock has risen 200% in the last six months, but has dropped 3.76% in the last one-month period. RAPT Therapeutics’ stock is trading 4.53% higher in the last five sessions on Wall Street.

(This is a developing story. Please check back for updates.)

Read all stories by Anubhav Mukherjee

Disclaimer: This story is for educational purposes only. We advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and circumstances may vary.